As noted previously, Opko and 19 other defendants, including Dr. Phillip Frost, its CEO and chairman, were named in a complaint filed on September 7 by the Securities and Exchange Commission.
The company will vigorously defend itself against these charges.
As noted previously, the SEC's lawsuit does not contain any allegations about OPKO's financial practices, financial statements or business practices.
Opko Health is a healthcare company. In diagnostics, its BioReference Laboratories is the nation's third largest clinical laboratory; GeneDx is a genetic testing business; the 4Kscore prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros 1 is a point of care diagnostics platform with PSA and testosterone as the most advanced in development.
In its pharmaceutical pipeline, Rayaldee is Opko's first pharmaceutical product to be marketed.
OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity in Phase 2 clinical trials, is among a new class of GLP-1 glucagon receptor dual agonists.
OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy), urinary incontinence and other conditions is in clinical trials.
The company's most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, is in Phase 3 trials and is partnered with Pfizer.
Opko has research, development, production and distribution facilities abroad.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer